28 results about "Lean body mass" patented technology

The present invention relates to the use of petrelintide to reduce body fat or inhibit gain of body fat whilst preserving lean mass.

The invention discloses a body fat prediction system and method based on a multi-band impedance signal, and relates to the technical field of big data analys.The method comprises the steps that impedance data of different segments under different frequency bands, the body fat amount, the lean body weight and the human body weight are collected; integrity verification is carried out on the impedance data, missing values are filled with mean values, abnormal values are removed and corrected, and meanwhile timestamp alignment is carried out; extracting features to construct an original impedance vector, and mapping the original impedance vector to a high-dimensional space through a random matrix to generate a random mapping function; constructing a time sequence regression model, taking the embedding dimension as an input layer, taking the body fat amount and the lean body mass as an output layer, and using mean square error calibration and back propagation updating; and through a mean square error weighting evaluation model, outputting a performance standard result. The system comprises a data acquisition module, a data preprocessing module, a random distribution embedding module, a time sequence model training module and a display module. The method can adapt to impedance characteristics of different crowds, is suitable for portable terminal or smart home body measurement, and can be used at high frequency in daily life.

The invention discloses lactobacillus delbrueckii with a muscle protection function in a fat reducing period as well as a product and application thereof, belongs to the technical field of microorganisms, and discloses lactobacillus delbrueckii subsp. Lactis Turb8 with the preservation number of CGMCC No.35627. The lactobacillus delbrueckii subsp. Lactis Turb8 has the advantages that the preservation number is CGMCC No.35627; the strain or the preparation thereof can effectively prevent or improve the accompanying problems of muscle loss and function decline in the process of applying fat-reducing drugs such as GLP-1 receptor agonists (such as liraglutide and semeglutide), and the effect of reducing fat but not reducing muscle is achieved. The strain disclosed by the invention can be used for remarkably increasing the lean body mass ratio of a user, increasing the muscle mass of lower limbs, increasing the cross sectional area of muscle fibers and improving muscle function indexes such as strength of four limbs and suspension endurance while keeping the original weight-reducing effect of a fat-reducing medicine. The invention also relates to microbial agents comprising this strain, various preparations, their use in the preparation of products for ameliorating (in particular drug-induced) muscle reduction.

The present disclosure relates to a method of preventing or treating a disease or disorder in a subject in need thereof, wherein administration of a composition of the present disclosure is effective to result in an increase of energy expenditure in the subject. The present disclosure provides a method of reducing fat mass and / or improving glycemic control in a subject in need thereof. The present disclosure provides a method of promoting weight loss and weight maintenance. The present disclosure provides a method of maintaining lean mass. Compositions for use in the methods include a compound of formula (I), (II), or (III), or pharmaceutically acceptable salts thereof, or in combination with a compound selected from the group consisting of an ACC2 inhibitor and an incretin mimetic.

This invention relates to the field of functional food technology, and discloses a muscle-building, lipid-lowering, and weight-loss composition, its preparation method, and its application. The composition, by weight, comprises: 25-45 parts of complex protein peptides; 5-20 parts of fruit and vegetable powder; 2-8 parts of medicinal and edible extracts; 3-12 parts of complex prebiotics; 1-6 parts of complex vitamins and minerals; 0.5-3 parts of probiotics; 0.5-5 parts of calcium β-hydroxy-β-methylbutyrate; and the remainder being food-acceptable excipients. This invention achieves significant lipid-lowering and weight-loss while effectively increasing lean body mass and muscle mass, and the active ingredients exhibit good stability.

The present invention relates to the use of an s100a8 / a9 and complement 3 inhibitor in the preparation of a drug for treating or preventing cachexia. The treatment or prevention of cachexia comprises increasing the body weight, lean body mass and fat mass, and increasing food intake in a cachectic subject, or preventing fat mass consumption, slowing the rate of body weight loss, the rate of fat mass loss and the rate of lean body mass loss, counteracting anorexia, muscle strength loss, fatigue and body weight loss, or improving abnormal biochemical results. Provided is a new understanding for the mechanism of energy balance regulation in cancer cachexia, with an emphasis on the effects of S100a8 / a9 and C3 in cancer cachexia. The inhibition of S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. Particularly, it is verified that an S100a8 / a9 inhibitor can prevent body weight loss, especially adipose tissue loss, in a cachectic subject, and significantly increases food intake in the subject.

The present invention provides a body composition estimation program and information processing device that estimate body composition based on measurable values ​​without invasiveness. [Solution] Terminal 1 includes a lean body mass estimation means for estimating lean body mass based on the user's age, gender, height, and weight; a muscle mass estimation means for estimating muscle mass based on the user's age, gender, height, and weight; a sarcopenia determination means for determining the likelihood of sarcopenia based on at least one of lean body mass and muscle mass; a survival rate evaluation means 104 for evaluating the survival rate based on at least one of lean body mass and muscle mass; and a standard index calculation means 105 for calculating a standard index for insurance enrollment based on at least one of lean body mass and muscle mass.

The present invention relates to an immunogenic compound comprising an ApoB100 epitope, an immunogenic composition comprising the same, and uses thereof. The immunogenic compound can be used to prevent or treat diseases caused by increased ApoB100 levels or increased lipid levels by inducing an immune response to the ApoB100 epitope. The immunogenic compound has a complementary mechanism to GIP-1R agonist obesity treatments, so their combined or concurrent administration can enhance weight loss and improve side effects associated with long-term administration of GIP-1R agonist obesity treatments by improving weight loss plateaus, delaying the yo-yo effect, and improving lean body mass reduction.

This invention relates to the use of S100a8 / a9 and complement 3 inhibitors in the preparation of medicaments for the treatment or prevention of cachexia, wherein the treatment or prevention of cachexia involves increasing the body weight, lean body mass, fat mass, and food intake of cachectic subjects, or preventing fat loss, slowing the rate of weight loss, slowing the rate of fat mass loss, slowing the rate of lean body mass loss, resisting anorexia, resisting muscle weakness, resisting fatigue, resisting weight loss, and improving abnormal biochemical results. This invention provides a new understanding of the mechanism of energy balance regulation in cancer cachexia, focusing on the roles of S100a8 / a9 and C3 in cancer cachexia. This invention finds that inhibiting S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. In particular, it demonstrates that S100a8 / a9 inhibitors can prevent the loss of body weight, especially adipose tissue, in cachectic subjects and significantly increase their food intake.

The present technology comprises methods of treating, preventing, reducing, or otherwise ameliorating one or more symptoms or conditions that may benefit from weight gain or a reduction in weight loss. The methods comprise administering a non-naturally occurring melanocortin analog of the present technology to a subject in need thereof. The methods may promote fat gain (e.g., epididymal fat or perirenal fat), increase muscle mass, increase body weight, accelerate weight gain, increase fat mass to lean mass ratio, improve body composition and / or BMI (e.g., for underweight conditions), increase waist circumference, increase cardiac mass, increase brain mass, or any combination thereof, relative to a control.

Applicant discloses methods and uses of the heteroaryl ketone fused azadecalin compound relacorilant for treating patients suffering from endogenous hypercortisolism (CS) (including Cushing's syndrome and Cushing's Disease) effective reduce or prevent the loss of tissue lean mass; in embodiments, the methods and uses are effective to increase tissue lean mass as compared to the patient's tissue lean mass prior to administration of relacorilant. The methods and uses of relacorilant for treating patients suffering from CS are further effective to reduce body weight and waist circumference of the patient.Therapeutic amounts of relacorilant may be between about 50 milligrams per day (mg / day) and up to about 800 mg / day, e.g., 100 mg / day, 200 mg / day, 300 mg / day, 400 mg / day, or 500 mg / day. The treatments may be oral treatments, and relacorilant may be administered with food, or without food. Relacorilant is (R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridine-2-yl)methanone, which has the structure:

A method of treating body composition resistance in a mammal is provided comprising administering to the mammal for a sufficient period of time nutrients comprising protein in an amount of 10-100g, creatine in an amount of 1-5g, vitamin D in an amount of 50-4000 IU, calcium in an amount of 100-1000 mg, and omega-3 fatty acids in an amount of 500-15,000 mg. In embodiments, the method additionally improves one or more of lean mass, muscle strength, body composition index, fat mass and % body fat, systemic inflammation levels, blood cholesterol levels and / or blood triglyceride levels

Provided are a composition including the microorganism Lactobacillus plantarum LMT1-48 (Accession No. KCTC13024BP) as an active ingredient for use in reducing body fat weight (BF) without reducing lean body mass (LBM) of the human body, and uses thereof.

A composition for consumption by an individual who is being treated with a GLP-1 agonist, including: at least one amino acid source in an amount effective to alleviate loss of lean body mass as a side effect of being treated with the GLP-1 agonist; at least one dietary fiber; and a therapeutically effective amount of at least one of a bioactive anti-emetic agent, an anti-bloating agent, an anti-diarrheal agent and an anti-constipation agent, wherein the composition is a premix or a ready-to-drink supplement effective to alleviate at least one additional side effect of being treated with the GLP-1 agonist, which is selected from nausea, bloating, vomiting, diarrhea and constipation. A method for alleviating loss of lean body mass and at least one additional side effect of being administered a GLP-1 agonist, includes feeding the composition to an individual who is being administered the GLP-1 agonist.

Disclosed herein are number embodiments relating to technologies for the use of postbiotic materials for the improvement of health. In certain embodiments, the composition is a postbiotic derived from at least one strain of bacteria wherein the at least one strain of bacteria comprises Propionibacterium freudenreichii UF (UF1). In certain specific embodiments contained in this disclosure, the postbiotic materials can lead to an reduction in body weight and an increase the portion of weight lost from fat rather than lean body mass.

Disclosed herein are compositions and uses for healthy weight management by providing a consumable composition comprising N-trans-caffeoyltyramine and N-transferuloyltyramine. Some embodiments provide for glucose management in a subject. Some embodiments provided include, for example, the consumable composition capable of supporting abdominal fat loss, visceral fat loss, maintaining lean body mass, and supporting normal blood glucose regulation.

Applicant discloses methods and uses of the heteroaryl ketone fused azadecalin compound relacorilant for treating patients suffering from endogenous hypercortisolism (CS) (including Cushing's syndrome and Cushing's Disease) effective reduce or prevent the loss of tissue lean mass; in embodiments, the methods and uses are effective to increase tissue lean mass as compared to the patient's tissue lean mass prior to administration of relacorilant. The methods and uses of relacorilant for treating patients suffering from CS are further effective to reduce body weight and waist circumference of the patient. Therapeutic amounts of relacorilant may be between about 50 milligrams per day (mg / day) and up to about 800 mg / day, e.g., 100 mg / day, 200 mg / day, 300 mg / day, 400 mg / day, or 500 mg / day. The treatments may be oral treatments, and relacorilant may be administered with food, or without food. Relacorilant is (R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridine-2-yl)methanone, which has the structure (A).

The present disclosure provides a method for improving muscle strength, muscle mass, performance, lean body mass and body composition, and decreasing fat percentage comprising administering an extract of aerial parts of Phyllanthus spp.. Aspects of the present disclosure also provides a formulation, a process for preparing the formulation, and use of 5 such formulation for improving muscle strength, muscle mass, performance, lean body mass and body composition, and decreasing fat percentage in a subject.

Provided herein are methods of increasing body weight and / or fat mass in a subject in need thereof, comprising administering to the subject a non-naturally occurring melanocortin analog. The methods may promote lean mass gain in the subject.

To provide a technique that enables prediction of weight loss of a subject through increased exercise.SOLUTION: A method of the present invention is for qualitatively predicting weight loss of a subject through increased exercise and comprises an acquisition step of acquiring at least one indicator selected from a group consisting of: physical indicators indicative of at least either of a physique and body composition of the subject, consisting of MQP (Muscle Quality Point), weight, trunk fat-free mass, and trunk muscle mass; and blood indicators measured from a blood sample of the subject, consisting of the blood red cell count and hematocrit value.SELECTED DRAWING: None

The present invention relates to compositions and methods for altering body composition in an individual, wherein the alteration in body composition is both an increase in muscle mass and a decrease in fat mass. The present invention also relates to compositions and methods for decreasing fat mass in an individual. The compositions and methods also increase muscle volume and lean body mass in an individual. The present invention also relates to compositions comprising a GDF8 inhibitor and an activin A inhibitor, and the use of such compositions to treat diseases and conditions characterized by increased fat mass and / or decreased muscle volume.

The present application relates to cachexia treatment. Administration of an antibody that specifically binds IL-1a is useful for treating cachexia and increasing the lifespan of a subject with cachexia. The present application provides the use of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of an anti- interleukin-1a antibody (anti-IL-1a Ab) in the manufacture of a medicament for reversing lean body mass loss in a human subject with cancer and weight loss, increasing the lifespan of a subject with cancer and weight loss by at least 10% compared to the subject's projected lifespan, increasing caloric intake in a subject with cancer and weight loss, increasing appetite in a subject with cancer and weight loss, increasing the quality of life of a subject with cancer and noticeable weight loss, and the medicament is repeatedly administered to the subject.

Provided herein are methods of reducing body weight and / or fat mass in a subject in need thereof, comprising administering to the subject a non-naturally occurring melanocortin analog alone or in combination with a weight loss agent. The methods reduce lean mass loss, maintain lean mass, or promote lean mass gain in the subject. The methods also reduce adverse effects associated with weight loss agents and / or melanocortin analogs.

The present invention relates to use of a GLP-1R / GLP-2R dual agonist, namely dapiglutide, to reduce body fat or inhibit gain of body fat whilst preserving lean mass.

The present disclosure relates to compositions and methods for improving glycemic control, increasing lean body mass, reducing fat mass, treating obesity, diabetes, and / or treating liver dysfunction in a subject. More specifically, the present disclosure relates to compositions comprising a GDF-8 inhibitor and a GLP-1 agonist and uses thereof, as well as compositions comprising a GDF-8 inhibitor, an activin A inhibitor and a GLP-1 agonist and uses thereof.

An electronic device obtains a target weight loss rate proportion of a user and a current weight of the user, where the target weight loss rate proportion is a weight loss rate proportion expected by the user, and the weight loss rate proportion is a proportion of a weight loss in first unit duration in the current weight. Fat loss content corresponding to the target weight loss rate proportion is determined, wherein the fat loss content is a ratio of fat amount in the reduced weight to the reduced weight. A calorie deficit of the user in second unit duration is determined based on the fat loss content corresponding to the target weight loss rate proportion, the target weight loss rate proportion, the current weight of the user, fat calories per unit weight, and lean body calories per unit weight.

Compositions and methods for the treatment of obesity, hyperlipidemia, fatty liver disease, cardiovascular disease and type II diabetes are described. Also described are compositions and methods for decreasing one or more of body weight, total fat, percent fat mass, visceral fat, epididymal fat, hepatic fat content, fasting blood glucose, decreasing white adipose fat (WAT) adipocyte size, or increasing percent lean mass. The compositions and methods involve PEGylated bilirubin.

This invention discloses a strain of *Lactobacillus delbrueckii* with muscle-protecting function during fat loss, its products, and applications, belonging to the field of microbial technology. The invention discloses *Lactobacillus delbrueckii* subspecies Turb8, with accession number CGMCC No. 35627. This strain or its preparations can effectively prevent or improve muscle loss and functional decline during the use of fat-loss drugs such as GLP-1 receptor agonists (e.g., liraglutide, smegglutide), achieving the effect of "fat loss without muscle loss." While maintaining the original weight-loss effect of fat-loss drugs, the strain of this invention can significantly increase the user's lean body mass percentage, increase lower limb muscle mass, increase muscle fiber cross-sectional area, and improve muscle function indicators such as limb strength and suspension endurance. This invention also relates to bacterial agents containing this strain, various preparations, and their application in the preparation of products for improving (especially drug-induced) muscle loss.